Warner S J, Auger K R, Libby P
J Immunol. 1987 Sep 15;139(6):1911-7.
Interleukin 1 (IL-1) alters several potentially pathogenic endothelial cell (EC) functions. The authors report here that recombinant human IL-1 (rIL-1) alpha (0.1 to 10 ng/ml) or IL-1-beta (1 to 100 ng/ml) induce concentration- and time-dependent increases in IL-1-beta mRNA levels in EC derived from adult human saphenous vein. rIL-1 induced IL-1-alpha mRNA only in EC treated concomitantly with cycloheximide (2 micrograms/ml). IL-1-beta mRNA production began within 1 hr of exposure to rIL-1, peaked after 24 hr, and declined thereafter. Actinomycin D prevented the appearance of IL-1 mRNA in rIL-1-treated EC. rIL-1 also induced the release of biologically active IL-1 from EC, which was inhibited by cycloheximide (1 microgram/ml). When compared on the basis of their activity in the thymocyte costimulation assay, rIL-1-alpha and rIL-1-beta were equipotent as inducers of IL-1 production by EC. EC stimulated with rIL-1 produced prostaglandin E2, which inhibits IL-1 production by other cell types and also decreases the responsiveness of thymocytes to IL-1. When EC were exposed to rIL-1 in the presence of indomethacin (1 microgram/ml), which blocked prostaglandin E2 production, greater amounts of rIL-1-induced IL-1 release were detected, although the inhibitor did not affect IL-1-beta mRNA levels. IL-1-induced IL-1 production was unlikely to be caused by endotoxin contamination of tissue culture media or IL-1 preparations, because the lipopolysaccharide (LPS) antagonist polymyxin B (10 micrograms/ml) blocked LPS-induced IL-1 production by EC but did not affect IL-1 release in response to rIL-1-beta (100 ng/ml). The IL-1-inducing property of rIL-1-beta was heat-labile, whereas heated LPS stimulated EC IL-1 production. The source of IL-1 in our cultures was not monocyte/macrophages, as treatment of EC with monoclonal antibody to the monocyte antigen Mo2 under conditions that lysed adherent peripheral blood monocytes did not affect production of IL-1 by EC in response to LPS (1 microgram/ml) or rIL-1-beta (100 ng/ml). IL-1 elicits a coordinated program of altered endothelial function that increases adhesiveness for leukocytes and coagulability. IL-1-induced IL-1 gene expression in human adult EC could thus provide a positive feedback mechanism in the pathogenesis of vascular disease including atherosclerosis, vasculitis, and allograft rejection.
白细胞介素1(IL-1)可改变内皮细胞(EC)的几种潜在致病性功能。作者在此报告,重组人IL-1(rIL-1)α(0.1至10 ng/ml)或IL-1-β(1至100 ng/ml)可诱导来自成人隐静脉的EC中IL-1-β mRNA水平呈浓度和时间依赖性增加。rIL-1仅在与放线菌酮(2μg/ml)同时处理的EC中诱导IL-1-α mRNA。IL-1-β mRNA的产生在暴露于rIL-1后1小时内开始,24小时后达到峰值,此后下降。放线菌素D可阻止rIL-1处理的EC中IL-1 mRNA的出现。rIL-1还可诱导EC释放具有生物活性的IL-1,这被放线菌酮(1μg/ml)抑制。当根据它们在胸腺细胞共刺激试验中的活性进行比较时,rIL-1-α和rIL-1-β作为EC诱导IL-1产生的诱导剂具有同等效力。用rIL-1刺激的EC产生前列腺素E2,其可抑制其他细胞类型产生IL-1,并降低胸腺细胞对IL-1的反应性。当EC在吲哚美辛(1μg/ml)存在下暴露于rIL-1时,吲哚美辛可阻断前列腺素E2的产生,尽管该抑制剂不影响IL-1-β mRNA水平,但可检测到更多的rIL-1诱导的IL-1释放。IL-1诱导的IL-1产生不太可能是由组织培养基或IL-1制剂的内毒素污染引起的,因为脂多糖(LPS)拮抗剂多粘菌素B(10μg/ml)可阻断LPS诱导的EC产生IL-1,但不影响对rIL-1-β(100 ng/ml)的反应中IL-1的释放。rIL-1-β的IL-1诱导特性不耐热,而加热的LPS可刺激EC产生IL-1。我们培养物中IL-1的来源不是单核细胞/巨噬细胞,因为在裂解贴壁外周血单核细胞的条件下,用针对单核细胞抗原Mo2的单克隆抗体处理EC并不影响EC对LPS(1μg/ml)或rIL-1-β(100 ng/ml)的反应中IL-1的产生。IL-1引发了内皮功能改变的协调程序,增加了对白细胞的粘附性和凝血性。因此,IL-1诱导的成人人类EC中IL-1基因表达可能在包括动脉粥样硬化、血管炎和同种异体移植排斥在内的血管疾病发病机制中提供一种正反馈机制。